Renocal-76 (diatrizoate) Disease Interactions
There are 2 disease interactions with Renocal-76 (diatrizoate):
Radiopaque Contrast Agents (Includes Renocal-76) ↔ Pheochromocytoma
Severe Potential Hazard, Moderate plausibility
Applies to: Pheochromocytoma
Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.
Diatrizoate (Includes Renocal-76) ↔ Congestive Heart Failure
Moderate Potential Hazard, Moderate plausibility
Applies to: Congestive Heart Failure
Due to the transitory increase in the circulatory osmotic load, injections with urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.
Renocal-76 (diatrizoate) drug Interactions
There are 262 drug interactions with Renocal-76 (diatrizoate)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.